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This paper summarizes the proceedings of a workshop held at Trinity Hall, Cambridge 
to discuss comparability and includes additional information and references to 
related information added subsequently to the workshop. Comparability is the need 
to demonstrate equivalence of product after a process change; a recent publication 
states that this ‘may be difficult for cell-based medicinal products’. Therefore a 
well-managed change process is required which needs access to good science and 
regulatory advice and developers are encouraged to seek help early. The workshop 
shared current thinking and best practice and allowed the definition of key research 
questions. The intent of this report is to summarize the key issues and the consensus 
reached on each of these by the expert delegates.
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A stakeholder workshop was held in Trin-
ity Hall, Cambridge University, on the 
14–15 September 2015 to discuss comparabil-
ity in cell therapy manufacturing. The focus 
of the workshop was on human pluripotent 
stem cell derived therapies.
Comparability is the regulatory require-
ment to demonstrate product equivalence 
(highly similar) after a process change [1,2]. 
Such process changes include a media com-
ponent change, a donor/starting material 
change, a manufacturing platform change 
and the introduction of a new manufactur-
ing site. A recent publication by current and 
former members and experts of the Com-
mittee for Advanced Therapies, EMA has 
emphasized that demonstrating comparabil-
ity maybe “difficult for cell-based medicinal 
products” [3].
The workshop aims were to share the EU 
regulatory position, understand the signifi-
cance of comparability and approaches to 
achieving comparability, and to define chal-
lenges to the community with the intent to 
communicate these more widely in order that 
they can be addressed by stakeholders per-
haps precompetitively and to help developers 
proactively address these issues.
It was attended by more than 50 cell ther-
apy development professionals from around 
the world with a wide range of backgrounds 
and reflecting a wide perspective. It was held 
under the auspices of the UK Regenerative 
Medicine Platform (UKRMP) and its cell 
biology, differentiation and manufacturing 
hub, The Pluripotent Stem Cell Platform 
with the intent that it would also inform the 
research of the hub.
This note summarizes the substance of the 
presentations and discussions at the workshop 
as below and references to related guidelines 
have been added. Some of the presentations 
and a preworkshop briefing paper [4] can be 
found at [5]. We are grateful to Dr Louise 
Bisset of the UK Medicines and Healthcare 
products Regulatory Agency (MHRA) for 
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an introduction to the problem of comparability from 
a regulatory perspective. This set the context for the 
workshop: the need for manufacturing process change 
is accepted, is inevitable and there are mechanisms to 
address it; presently the ‘product is the process’ since 
“a biological medicinal product cannot be fully char-
acterized;” significant changes observed in the product 
characteristics after manufacturing process changes 
may require further nonclinical and clinical studies to 
investigate any impact on efficacy and safety.
To ensure that pluripotent stem cell products get to 
market, there are some key translational issues which 
need to be addressed including manufacturing. Liv-
ing cells add particular complexities, which need to be 
addressed in manufacturing system design and within 
manufacturing protocols. Change management proto-
cols [6] describe specific changes that an organization 
would like to implement following product approval 
and how these would be prepared and verified and are 
important to manufacturers and product developers as 
well as the regulator. They provide a record, and later, 
part of a regulatory submission of the strategy adopted 
by a manufacturer in order to manage post-approval 
changes including for example, comparability issues. 
The submission needs to be in a form that permits 
the regulator to assess and approve or challenge the 
adequacy of the strategy. Without being able to dem-
onstrate comparability it is hard to carry out process 
improvement, and particularly to transfer a product to a 
second manufacturing site – such a as a Contract Man-
ufacturing Organization (CMO) or additional manu-
facturing sites. This is an instance of the requirement 
for practical interchangeable manufacturing (see Box 1) 
where a product specification includes limits of critical 
attributes related to function and the key problem is the 
control of variation within these limits [7]. The goal of 
the comparability exercise is to ensure the quality, safety 
and efficacy of drug product produced by a changed 
manufacturing process, through collection and evalu-
ation of the relevant data to determine whether there 
might be any adverse impact on the drug product due 
to the manufacturing process changes [1]. Manufactur-
ing experience in other sectors has shown that manu-
facturing variability can be reduced by automation of a 
manual process but emphasizes that mechanization (see 
Box 1) of the process gives more significant gains.
Justification of product specification & limits
Product testing strategies are at the heart of product 
specifications, process development and understand-
ing. Product release specifications do not establish 
full characterization of the product and therefore 
whilst ensuring product consistency, form only part 
of the evidence required to demonstrate comparabil-
ity. Comparability protocols consequently must con-
sider the risks associated with any proposed process 
change and must prescribe the way in which any such 
evidence will be gathered. In doing so attention must 
be paid to the process instructions (including standard 
operating procedures), critical process parameters, in-
process controls and critical quality attributes (CQAs) 
in addition to the product specification to ensure and 
demonstrate comparability (see Box 2).
When deciding on whether to make changes, an 
approach based on risk should be taken and practical 
limitations must be considered. Prior to undertaking a 
comparability study, it is important to understand what 
is expected and this will depend on the nature of the 
change and the stage of the product’s lifecycle. Histori-
cal data and process development data should be used to 
set comparability acceptance criteria for selected CQAs 
and all data analyzed following the comparability data-
gathering exercise to support a claim of comparability at 
the quality level. Any differences should be explained, 
in terms of potential effect on safety/efficacy. Where 
the effect on safety/efficacy cannot be predicted then 
further nonclinical or clinical data may be required.
Assays which enable the detection of variation as a 
result of any change are useful to inform conclusions. 
Assays should be shown to be capable of detecting 
quality changes. Potency and mode of action assays 
– which are often the most complex – are the most 
critical when trying to assess comparability.
It is important to ensure that the product and pro-
cess platform is correct at the start of the process and to 
not rush into the clinic too early, in order that changes 
can be made as process improvements rather than pro-
cess alterations. Organizations can also record infor-
mation on changes which occur during early product 
development in nonmandatory documents such as a 
cell history file [10]. Where significant changes need 
to be made to the manufacturing process, it is advis-
able to make these before pivotal clinical trials. Process 
improvements to an established/authorized process 
can be made if they do not trigger a marketing autho-
rization (MA) variation, in other words, where they do 
not relate to a specification or manufacturing method 
registered in the clinical trial authorization or MA. 
These changes are conducted under good manufactur-
ing practice (GMP) change control in accordance with 
the principles of quality risk management [11,12].
By the very nature of the starting materials, variation 
is inherent in these products. Wide upper and lower 
acceptance limits can be established where validated 
(i.e., upper and lower limits do not adversely affect the 
quality of the product) and quantity permits so that 
future manufacture of these products could therefore 
accommodate or control this variation. Specifications 
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for starting materials are often difficult as it is difficult 
to establish quantitative acceptance criteria. Where 
materials are available in small quantities, unless abso-
lutely necessary some tests could waste material, for 
example, material obtained from a human biopsy. In 
such a case the size and appearance may be sufficient 
as controls. Additional controls over clinical collection 
techniques and practices may be required. Specifica-
tions should be set considering manufacturing process 
requirements.
The problem of variation in starting materials is 
significant, but the desire or ability within the field to 
control it does not appear to be increasing over time. 
Also, it may not be possible to control the variability of 
starting materials.
Most currently applied statistical tools use normally 
distributed data, however input variation for cell-based 
therapies tends to be non-Gaussian in form and therefore 
there is a need for appropriate statistical tools that allow 
for the disproportionate effect of the kurtosis. Under 
such circumstances the probability of an outlier is higher 
and more serious in impact than in conventional settings 
and statistical process control methods may break down.
It should also be recalled for therapeutics that out-
liers cannot be excluded as each outlier represents an 
individual patient requiring a treatment. Also as result 
of the wide range of variability between patients, any 
individual patient is poorly characterized by the mean. 
Further the nature and character of the cells will only 
be one parameter on which the success of the product 
can be measured. Most cell therapies are not first-line 
treatments and it is likely that a cell therapy may only 
be one component of a patient’s treatment. Asymmetri-
cal specifications are problematic from the perspective 
of a developer and in particular ranges of failure at 
the lower limit of the specification must be carefully 
considered. Where the underlying data distribution is 
asymmetric, manufacturers need to take this into con-
sideration when setting limits so that the probability 
of staying within the specification is the same for both 
upper and lower limit.
Markers currently being used for cell identity are 
determined on a largely empirical basis and therefore 
future discoveries about the true mode of action may 
render their use in release criteria inappropriate in the 
long term. Consequently there is more work to be done 
to ensure we are measuring quality meaningfully.
Qualification of the starting cells will, where sup-
ply allows, be critical to help understand and reduce 
input variation. Automation of assays can be used as a 
tool to reduce variation, but only if the automated plat-
forms are validated and their contribution to variation 
is understood. Automation is expensive to implement 
and should be deployed at points in the process where 
it will exert the most influence on control of product 
quality. There is an opportunity for the manufacturing 
community to share experience of what can be achieved 
with respect to process variation and its control.
Box 1. Learning from conventional manufacturing.
•	 Interchangeable manufacturing [8] – interchangeable parts are parts (components) that are, for practical 
purposes, identical. They are made to specifications that ensure that they are so nearly identical that they 
will fit into any assembly of the same type. One such part can freely replace another, without any custom 
fitting (such as filing). This interchangeability allows easy assembly of new devices, and easier repair of 
existing devices, while minimizing both the time and skill required of the person doing the assembly or repair. 
Interchangeability was an eighteenth century Enlightenment ideal [8] as was the metric system. Practical 
interchangeability is distinguished from theoretical interchangeability by the application of limits related to 
product function. A critical step in the realization of interchangeability in conventional manufacturing, in 
particular the ability to manufacture the same product at a number of sites, was the development of systems 
of gauges that allowed measurements that could be related to function
•	 Six Sigma [9] – is a set of techniques and tools for process improvement. It was introduced by engineer Bill 
Smith while working at Motorola in 1986 and based upon the principles of statistical process control. Jack 
Welch made it central to his business strategy at General Electric in 1995. Today, it is used in many industrial 
sectors. Six Sigma seeks to improve the quality of the output of a process by identifying and removing the 
causes of defects and minimizing variability in manufacturing and business processes. It uses a set of quality 
management methods, mainly empirical statistical methods, and creates a special infrastructure of people 
within the organization, who are experts in these methods. Critically process capability is measured and 
understood to drive conformance to specification. Each Six Sigma project carried out by a team within an 
organization follows a defined sequence of steps and has specific value targets, for example: reduce process 
cycle time, reduce pollution, reduce costs, increase customer satisfaction and increase profits
•	 Automation vs mechanization – it is important to distinguish between the automation of a manual process, 
the replication of a manual process by a machine typically to make it more repeatable, reduce risk or enhance 
cleanliness by removing humans from the manufacturing environment or reduce recurrent costs; and the 
mechanization of a process where the machine achieves better than human performance typically for 
example, by being more powerful and/or precise
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Product characterization & assays
Product characterization is a fundamental part of 
manufacturing that poses particular challenges to the 
demonstration of comparability in the context of cell 
therapy medicines.
There is consensus that for specifying cellular prod-
ucts satisfactorily a selected number of key character-
istics should be measured by quantitative assays that 
identify cellular identity and function with a high level 
of sensitivity; it is desirable to use orthogonal assays to 
measure key characteristics. However, variability that 
could affect a comparability assessment can arise from 
multiple sources in manufacturing with biological, pro-
cess and analytical variability the most important ones. 
Delegates agreed that some of the biological variances 
cannot be controlled due to the intrinsically complex 
nature of cells. Nevertheless, in principle it is possible 
to design controllable characterization assays for cellu-
lar products so that reproducibility of assays is increased 
and meaningful biological discrepancies can be assessed.
Variability of analytics is a particular issue for cell 
therapy products as they differ from other biologics in 
the lack of established standard references to aid the 
construction of robust assays. The workshop recog-
nized the need for the establishment of a framework 
for reproducible analytics (currently a topic of discus-
sions led by the National Institute of Standards and 
Technology [MD, USA] and the National Institute 
for Biological Standards and Control [Hertfordshire, 
UK]) for cell therapy with the involvement of aca-
demia, industry and national and international stan-
dards organizations that could provide criteria and 
tools to facilitate the transition from research-grade to 
industry-grade characterization.
Case studies of common characterization techniques 
(such as gene expression) revealed that variability arises 
with each step but can systematically be reduced via 
automation of manual procedures and standardiza-
tion of data analysis. Several techniques, such as 
fluorescence-activated cell sorting, are already mov-
ing in this direction with new platforms and reference 
systems suited for comparability between laboratories 
and equipment. However, many parameters currently 
used to assess cell culture quality are still qualitative 
and subjective based on operator expertise, often via 
manual optical microscopic inspection. The inclusion 
of quantitative software based live cell imaging cou-
pled with predefined thresholds within algorithms is 
encouraged for characterization during development.
Understanding the mechanism of action of the 
product underpins the development of potency assays 
required for in-process and release testing, a complex 
process that has to be tailored to each specific drug 
product. A number of challenges are associated with 
every phase of potency assay design including: robust-
ness, time to develop and perform the assay, availabil-
ity of reference material and performance. Developers 
recommend screening a matrix of potency assays dur-
ing product development that would be later narrowed 
down to a panel of key, often multi-parameter assays. 
Utilizing multiple potency assays would also help to 
risk assess the product and cross validate assays.
Furthermore, potency assay development is a 
dynamic process that needs to be linked to clinical 
data, which are critical to correlate safety and efficacy 
of the product to the product characteristics. Overall, a 
pragmatic approach to product characterization is one 
that would define a ‘window of system behavior’, with 
particular attention to the definition of the limits, so 
that a level of biological variability is tolerated but the 
process as a whole is under control.
Principles of comparability & risk assessment 
approaches
Although the International Council for Harmonisation 
(ICH) of Technical Requirements for Pharmaceuti-
cals for Human Use Q5E document on Comparabil-
ity of Biotechnological/Biological Products Subject 
Box 2. Glossary of pharmaceutical development terminology.
•	 CQA – a physical, chemical, biological or microbiological property or characteristic that should be within an 
appropriate limit, range, or distribution to ensure the desired product quality
•	 CPP – a process parameter whose variability has an impact on a critical quality attribute and therefore should 
be monitored or controlled to ensure the process produces the desired quality
•	 A pivotal clinical trial is that which provides the most significant data used to support the marketing 
authorization application. Usually this is the Phase III trial
•	 Comparability protocol – US FDA guidance for industry defines “a comparability protocol is a well-defined, 
detailed, written plan for assessing the effect of specific CMC changes in the identity, strength, quality, purity 
and potency of a specific drug product as these factors relate to the safety and effectiveness of the product. 
A comparability protocol describes the changes that are covered under the protocol and specifies the tests 
and studies that will be performed, including the analytical procedures that will be used, and acceptance 
criteria that will be achieved to demonstrate that specified CMC changes do not adversely affect the product. 
The submission of a comparability protocol is optional”[15]
CMC: Chemistry, manufacturing and control; CPP: Critical process parameter; CQA: Critical quality attribute.
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to Changes in Their Manufacturing Processes [1] is 
specifically for proteins and small molecule biolog-
ics, the principles apply to products using pluripotent 
stem cells. The main ‘overarching’ regulatory guideline 
‘guideline on human cell-based medicinal products’ [13] 
contains a section on comparability which makes refer-
ence to ICH Q5E. For planned changes, a risk-assess-
ment approach should be followed to establish the focus 
of the comparability study, assess the change(s) and the 
impacts on the product CQAs also taking into account 
the fact that changes might have a cumulative effect 
on the product. The comparability study depends on 
the extent of the change and the stage in the products 
development when the change takes place (for example 
pre- vs post-pivotal clinical trials).
It is important to realize that it is not sufficient to 
rely on routine specification tests (i.e., the release cri-
teria) when seeking to demonstrate comparability fol-
lowing a process change, data from in-process controls, 
extended characterization and stability studies will also 
be required comparability protocols should be designed 
to consider all outcomes and acceptance criteria must 
be prespecified. Ideally the data generated from prod-
uct characterization and in-process checks (i.e., qual-
ity data) would be sufficient to provide the evidence 
of comparability without resorting to further non-
clinical or clinical bridging studies, but where changes 
are identified and effect on safety or efficacy cannot be 
predicted or ‘ruled-out’ further non-clinical or clinical 
studies may be required. A risk assessment approach 
should be used to focus and define the experimental 
program; address issues critical-to-development; and 
identify and justify key putative process changes, for 
example using risk assessment methods and principles 
as outlined in ICH Q9 [11], or other suitable methods.
Importantly from a regulatory perspective, non-
clinical studies (remembering the 3R principles [14]) 
and clinical trials used to demonstrate comparability 
must be sufficiently statistically powered to show that 
the product is within the tolerance limit, recalling the 
regulatory perspective that the mode of action is veri-
fied in the pivotal clinical trial (see Box 2). Crucially, 
where manufacturing changes are made to the prod-
uct, following pivotal clinical trials, the product must 
be shown to be sufficiently comparable to the clinically 
tested material. Some level of comparability needs to be 
conducted, commensurate with the degree of change, 
whatever stage of the development lifecycle the change 
is made, including early changes.
Manufacturing control & process modeling
There is a requirement to control manufacturing pro-
cesses to ensure that the product is equivalent after a 
change. Controlling the process may be achieved by 
passive control by setting process limits, and by active 
control involving feedback loops. Ideal manufacturing 
control development will take the fastest route to the 
process knowledge (operating limits, control preci-
sion) to allow informed process design to meet objec-
tives and manage process risk – the greater the process 
knowledge, the lower is the risk of change.
Well-designed manufacturing controls are especially 
important when there is a large parameter space with 
very complex interactions, poor control relative to the 
allowable limits, insufficiently developed measurement 
capability and the process dynamics are very compli-
cated. There is an advantage to developing models of 
cell manufacturing process protocols in order to predict 
those experiments that should be performed in order 
to confirm impact of the proposed change upon the 
manufacturing process. Such models might be useful 
if used to reduce the parameter space for experiments, 
rather than to replace them and if the model predic-
tions are subsequently validated using appropriate 
experimental studies
Comparability plans & protocols
One of the reasons for the lack of resources spent on 
developing comparability and control tools is that the 
developers of these products are often academia, hospi-
tals and small–medium enterprises who are unable to 
afford regulatory expertise, regulatory support struc-
tures or funding. Early engagement with MHRA in the 
UK or other regional regulator is needed. The product 
characterization associated with different manufactur-
ing protocols is frequently squeezed to a late stage in 
the development process.
Examples where a demonstration of comparabil-
ity post-marketing authorization would be required 
include: change of starting materials/reagents, intro-
duction of a new manufacturing process step and the 
introduction of a new site. Practice differs between the 
US and the EU, although the intention is similar: to 
provide confidence in the continued quality, safety and 
efficacy of the product after the change. In the USA 
the comparability protocol describes, prospectively, 
the planned change to the manufacturing process in 
the form of a prior approval supplement which, when 
reviewed by the US FDA, will determine whether the 
planned change can be reported in a category lower 
than that required without a full comparability pro-
tocol. The comparability protocols will be acceptable 
only if certain conditions have been met: the product 
can reasonably be expected to satisfy the required qual-
ity criteria, the process and plant have been qualified 
and the analytical assays that are required in order to 
demonstrate comparability have been developed and 
validated. In such cases, the regulator will expect that 
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the identity, strength, quality, purity and potency of 
the product must be verified as part of the comparabil-
ity protocols. Process improvements may also invali-
date assays by changing the background impurity 
profile on which the assays were validated.
The comparability protocols must relate a robust con-
cept of the mechanism of action for the product to the 
product quality attributes. The putative process changes 
must be listed along with the historical data (both release 
and in process characterization). The comparability pro-
tocols must set out prescriptive decision-making criteria 
together with the data requirement.
In the EU there is a mechanism by which the manu-
facturer of the licensed product can submit a compa-
rability plan for approval by the regulator, before the 
actual study is carried out. The manufacturer submits 
what is called a ‘post-approval change management 
protocol’ as a variation [16], which details the compara-
bility plan. The comparability study is performed and 
the data/results are then submitted as a further more 
‘minor’ variation for the final conclusion on compara-
bility. This approach is often used by manufacturers 
for larger manufacturing process changes (e.g., intro-
duction of a new site). Changes to manufacturing pro-
cesses post licensing usually occur many times during a 
products life-cycle. These changes are submitted to the 
regulator as variations (usually for biological products 
these are type II variations) and some form of com-
parability assessment will be required, the extent of 
which depends on the nature of the change. Changes 
which occur prior to approval and during historical 
product development should be documented in the 
manufacturing process development sections of the 
dossier (both drug substance and drug product).
Future therapeutic landscape, induced 
pluripotent stem cell & haplobanking
Taking a forward look at the therapeutic landscape, 
transplantation of allogenic therapies is difficult due to 
the requirement for either a suitable match or immuno-
suppression. The Global Alliance for iPSC Therapies 
(GAiT) [17,18] project aims to create international banks 
of stem cells which are selected to be immunologically 
compatible with a large proportion of the potential recip-
ient population by covering a wide range of haplotypes 
for ABO and HLA antigens. Though these banks of 
cells are to be the starting material for the final thera-
peutic, the concepts of comparability need to be applied. 
There are potential differences between cell lines derived 
from different donors, different tissue sources, different 
methods of isolation and different methods of induce-
ment of pluripotency and different expansion and 
banking techniques. To achieve comparability between 
banks, the alliance is working toward developing guide-
lines for a global production process and critical quality 
control (QC) tests, defining common QC techniques, 
common specifications of the banks and engaging with 
regulatory bodies to ensure that the validation packages 
being developed are acceptable to regulatory bodies in 
different jurisdictions. The alliance is also examining 
reference materials to compare the banks to validate 
comparability between banks. The variability in the 
banks is expected to be large due to the high-biological 
variability, variability between manufacturing sites and 
operator variability for manual processes.
Plenary summary & conclusion
The plenary session considered the current limita-
tions to, and best practice for, process development for 
a new cell therapy. The main emphasis in discussion 
was on the relationship between the features of the pro-
cess (critical process parameters) and confidence that 
measurable characteristics of the product (CQAs) are 
genuinely responsible for efficacy and safety within its 
micro-environment and for the target indication and 
patient population. A key outcome of this session was a 
summary of lessons for developers as shown in Table 1.
The session included key informal input from devel-
opers. Developers emphasized the value of an approach 
based on risk management and that there is a need start 
the risk assessment as early as possible. In view of the 
limited resources of many small–medium enterprises 
in the sector the careful and early application of a risk-
based approach to product characterization is most 
important. An early dialog with the relevant regulators 
should be part of this work to ensure that the strategy is 
adequate and rational.
A balance must be struck between obtaining suffi-
cient characterization data with strong links to the puta-
tive mode of action (demonstrated or based on prior 
knowledge) and measurement of excessive numbers of 
features simply because of a lack of confidence. Novel 
assays may be required, these can be used provided they 
are shown to be suitable and are validated.
An important point is to start the development of the 
potency assay early. Without this assay it is very difficult 
to satisfy the regulatory requirement to demonstrate 
control of product ‘strength’. An understanding should 
also be gained of which components of the product 
should be classed as impurities, although, with a prod-
uct consisting for example of a mixture of cell types, 
this may not always be possible and the drug substance 
may have to be defined in terms of the spectrum of cells 
present. Biomarkers should not be accepted uncritically 
for this purpose because some may not be indicative of 
product quality, safety or efficacy, will be an ongoing 
production cost burden and may lead to unnecessary 
investigations should variation be found batch-to-batch. 
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Wherever possible the chosen assays should be simple, 
and consideration should be paid to the likely contin-
ued availability of reagents/consumables. Assays should 
be validated for use. For licensed products this means 
conformance to ICH Q2(R1) [19]. Different assays 
would normally be used for identity, purity and potency 
testing. Developers suggest that assays are based upon 
protocols published in peer-reviewed journals, however 
given the pace of change in this area may be new and 
unique to an organization.
It is important not to do analytical experiments out 
of curiosity but only after clarifying the purpose, risks 
of conducting them and the scope of the work. This is 
because the results must be followed up if unwelcome 
effects are found. It is preferable to do the tests that are 
needed and to make sure that the risks of the outcome 
are understood and managed.
The quality, safety and efficacy of the drug product 
may be affected by events that take place in ‘the last 
one hundred yards’. As far as possible it is desirable to 
control the administration of the product by develop-
ing dosage forms and delivery vehicles that are able to 
maintain the drug product within an acceptable enve-
lope of parameters such as temperature, time and fluidic 
stress or rate of delivery.
Some of these concerns are legitimate research top-
ics, ‘measurement of biology’ for instance is not a solved 
problem and developers need to be clear on those areas 
that remain research issues. Research should be funded 
in methods that permit better interpretation of the sig-
nificance of biomarkers. The current guidance is help-
ful but does not provide sufficient information to drive 
method development. There are a number of decision-
making tools available that enable the developer to 
decide at what points they should conduct analysis of 
measurable features that exercise the most influence 
over product properties. Everyone needs viability assays 
and the community should start by creating robust 
comparable protocols for these.
Discussions at the workshop emphasized the need to 
address the requirements of comparability and security of 
supply simultaneously and that situations where a compa-
Table 1. Lessons for developers.
Number Lesson
1 Talk to the regulators in your jurisdiction about proposed changes as early as possible
2 Be clinically specific and have a well-defined product and process understanding
3 Understand variation; understand allowable operating limits; control variation
4 Developers should focus on the key steps of: (1) process transfer; (2) product and process 
comparability
5 Measure the right process parameters and intermediates as well as the final product to establish 
a baseline: product and process knowledge will require measurements over and above product 
release criteria
6 Use a risk-assessment approach to define the experimental program necessary for comparability 
and start as early as you can; use the analysis as a mechanism to direct resource
7 Key stage gates and value inflection points are pivotal preclinical work, and pivotal clinical trials 
– key studies need to be done before these
8 Recall that in the EU Phase III clinical trials are intended to verify putative modes of action
9 Use historical analytical and process data to help set limits
10 Be careful with the definitions of active substance, strength and product and process impurities
11 Characterize as much as you can as early as you can, characterization will be product specific. Do 
not confuse identity with potency; question the value of your biomarkers
12 Understand your assay and equipment; use appropriate and sustainable equipment and 
technology to future proof in case you need to reproduce the technique beyond the lifetime of 
more bespoke instruments
13 All assays used should be validated for the intended use. For licensed products this means 
conformance to International Council for Harmonisation Q2(R1) [19]. Different assays would 
normally be used for identity, purity and potency testing.
14 Use assays that are able to detect the change you aim to execute
15 You may have to run processes ‘side by side’ (rather than comparing the changed process to 
retained samples)
16 Academic developers require regulatory support in manufacturing scale-up
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rability protocol may be required must be identified and 
addressed early in the development process. Key value 
inflection points for addressing comparability issues are 
before pivotal preclinical work and before pivotal clini-
cal trials. Exchanges at the workshop also identified that 
there is still a need for the manufacturing community to 
convince other stakeholders of the value of the applica-
tion of automation and mechanization approaches to 
control variation. A recurring theme of the workshop was 
the need to keep unpicking complexity and variation in 
cell therapy manufacturing, variation sources (biological, 
technical and operator) and the consequences of variation 
and how to address/control them. There is an opportu-
nity to put mechanisms in place to share learning on the 
variation encountered by developers.
The key precompetitive activity arising from the 
workshop was the need to develop a framework for 
comparative analytics including methods of data pre-
sentation. This could include criteria for application 
of methods and tools; precompetitive interlaboratory 
comparisons and assay development; and analytical 
reference materials.
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